▼ Summary
– Miraqules developed a nanotechnology powder that mimics blood clotting proteins and can stop bleeding within one to two minutes when applied.
– The company is a Top 20 Startup Battlefield finalist and will present its technology at TechCrunch Disrupt 2025 in San Francisco.
– CEO Sabir Hossain discovered the technology accidentally while working in a research lab, creating a powder from dismantled particles that clotted blood rapidly.
– Miraqules has secured 11 patents across seven countries and expects regulatory clearance in India soon, with FDA clearance anticipated in 2026.
– The company has raised less than $700,000, is piloting in an Indian trauma center, and has interest from hospital chains and the Israeli Defense Forces.
Miraqules, a pioneering biotech firm based in Bengaluru, is set to showcase its revolutionary blood-clotting nanotechnology at TechCrunch Disrupt 2025 in San Francisco. The company’s innovative powder mimics natural clotting proteins, forming fibrous structures at room temperature that absorb blood rapidly and halt bleeding within one to two minutes. This breakthrough promises to transform emergency medical responses, particularly in trauma situations where every second counts.
The journey to this innovation began almost by accident with co-founder and CEO Sabir Hossain. Though he initially aimed to follow his father’s entrepreneurial path, Hossain never anticipated launching a biotech venture inspired by a personal family crisis, a severe accident that nearly cost his father his life due to uncontrolled bleeding. While pursuing graduate studies in biomedical engineering, Hossain worked in a biomaterials research lab, tasked with assisting a doctoral student focused on creating 3D structures to support bone tissue regeneration. Ironically, his repeated attempts to synthesize the material resulted in consistent failure, with the structures breaking down each time.
Rather than discarding the failed material, Hossain ground the dismantled particles into a fine powder. He brought this substance to another research group struggling with blood-clotting solutions. To everyone’s surprise, the powder caused blood to clot in just five to ten seconds. This unexpected success sparked intensive investigation. Hossain and his colleagues identified a novel method for combining readily available materials into a nanomaterial that effectively imitates the body’s natural clotting mechanisms.
Soon after, Hossain partnered with childhood friend Mubeen Midda to refine the technology for real-world application. Operating on a shoestring budget, they focused on developing a practical and scalable product. Their persistence has paid off: Miraqules now holds eleven patents across seven countries, including the United States, India, and Israel. The company has kept costs remarkably low, achieving these milestones with less than $700,000 in funding, primarily from grants.
Currently, Miraqules’ clotting powder is undergoing pilot testing at a trauma care center in India. The company anticipates receiving regulatory approval in India within the coming months and is progressing toward clearance from the U.S. Food and Drug Administration by 2026. Early engagement with the FDA through pre-submission consultations provided crucial guidance, streamlining the path to compliance and market readiness.
Interest in the technology is growing rapidly. Ten major hospital chains in India have expressed potential collaboration interest, as has the Israeli Defense Forces, highlighting the product’s value in both civilian and military medical contexts. As a Top 20 Startup Battlefield finalist, Miraqules will present its life-saving innovation on a global stage at TechCrunch Disrupt, offering a compelling example of how determined problem-solving can yield transformative health solutions.
(Source: TechCrunch)
